CD137L-DCs induce potent Th1 and type 1 CD8+ T cell (Tc1) responses, leading to strong immune responses against virus-associated tumor cells, making them a promising candidate for virus-associated cancer immunotherapy [14]. This evidence concerns the gene TNFSF9 and neoplasm.